moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

6 January 2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA, for approval of Viibryd (vilazodone) for major depressive disorders and Colobreathe (colistimethate sodium) to treat lung infections in patients with cystic fibrosis.

moksha8 and US drugmaker Forest Laboratories (NYSE: FRD) have also amended their current strategic alliance (The Pharma Letter October 24, 2012. Forest will no longer have ongoing financial obligations under the alliance and will no longer have the option to acquire moksha8 in a merger transaction. moksha8 will retain the exclusive license to commercialize Viibryd, and moksha8 is working to expand its relationship with Forest to include other products for Latin America in the future. Other financial terms were not disclosed.

Under license from Merck Serono

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK